The Brno-based early-stage drug discovery company CasInvent announced the completion of a follow-up investment round of €1.3 million to develop new Casein Kinase 1 Inhibitors for the treatment of leukemia and solid tumor. The round was led by KHAN Technology Transfer Fund I and i&i Biotech Fund.
- Established in 2020 as a spin-off of Masaryk University in cooperation with the investment partner biotech hub i&i Prague, CasInvent Pharma develops new therapeutic options for the treatment of selected malignancies.
- The company tests the compounds that inhibit the enzyme Casein Kinase 1, which is used for diseases that currently have limited treatment options.
“CK1 inhibition provides a novel mechanism of action in different cancer indications, which needs to be exploited in the clinic. We believe that our compounds have the potential to offer novel alternatives of cancer treatment for patients with a high unmet medical need,”
comments Alexander Scheer, CSO of CasInvent Pharma.
- The fresh capital was led by KHAN Technology Transfer Fund I and i&i Biotech Fund. KHAN Technology Transfer Fund I is a Dortmund-based venture capital fund that invests in healthcare and life sciences industries. i&i Bio is a Luxembourg-based VC firm that invests in innovative European Life Sciences companies focused on drug discoveries and medical devices.
- CasInvent will spend the fresh investment to further develop its technology and strengthen portfolio of casein kinase inhibitors.
